Education
About Us
Working with TipRanks
Follow Us
Icon plc (ICLR)
NASDAQ:ICLR
ICLR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$125.10 - $328.04
Previous CloseN/A
Volume330.38K
Average Volume (3M)1.51M
Market Cap
$13.36B
Enterprise Value$14.73B
Total Cash (Recent Filing)$526.70M
Total Debt (Recent Filing)$3.56B
Price to Earnings (P/E)17.7
Beta0.98
Next Earnings
Oct 22, 2025EPS Estimate
3.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.26
Shares Outstanding77,772,130
10 Day Avg. Volume1,053,604
30 Day Avg. Volume1,512,441
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit6.61
Enterprise Value/Ebitda9.59
Forecast
1Y Price Target
$213.38Price Target Upside22.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Financial PerformanceICLR's impressive bookings beat targets, with net bookings exceeding expectations by 8% and a net book-to-bill ratio coming in well above target.
Market PositionICLR is seen as a structural winner in the clinical CRO space, benefitting from its market-leading position and the industry's cyclical bottoming.
Operational StrategyICLR leveraged its strong balance sheet to repurchase $250 million worth of stock, intending to remain active in share buybacks.
Bears Say
Market VolatilityICLR's recent results have not been immune to market volatility, with fairly muted expectations due to potential revenue pressure and excess cancellations.
Operational ChallengesICLR halted screening and dosing activities for new subjects, although half of the planned subjects have already been enrolled and dosed.
Regulatory ChallengesThe ongoing saga of the BARDA trials for ICLR took another negative turn with a delay, impacting the stock negatively.
Icon News
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $125.10 and its highest was $328.04 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $13.36B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Oct 22, 2025 which is in 54 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Jul 23, 2025. The company reported $3.26 earnings per share for the quarter, beating the consensus estimate of $3.188 by $0.072.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 3.33.
How many shares outstanding does Icon plc have?
Icon plc has 77,772,130 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $3.26 in its last earnings report, beating expectations of $3.188. Following the earnings report the stock price went up 16.153%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
Icon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$213.38 (22.63% Upside)
$213.38 (22.63% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 573.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $178.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.81%
12-Months-Change
Fundamentals
Return on Equity
8.30%
Trailing 12-Months
Asset Growth
-2.16%
Trailing 12-Months
Company Description
Icon plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
ICLR Company Deck
ICLR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong gross business awards, improved cost management, and operational advancements, with significant share repurchases indicating financial strength. However, elevated cancellations and decreased year-on-year revenue posed challenges. The sentiment is balanced with promising growth but also notable obstacles.View all ICLR earnings summariesICLR Stock 12 Month Forecast
Average Price Target
$213.38
▲(22.63% Upside)
Technical Analysis
Ownership Overview
0.39% Insiders
30.24% Mutual Funds
44.08% Other Institutional Investors
23.92% Public Companies and
Individual Investors